GlycoNex (ROCO:4168) Long-Term Debt: NT$475.96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4168 GlycoNex Inc ROCO:4168
57 GF Score
Price NT$22.70
GF Value NT$70.97
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is GlycoNex Long-Term Debt?

GlycoNex ROCO:4168 57 Long-Term Debt is NT$475.96 Mil as of Mar. 2026. GuruFocus rates ROCO:4168 with a GF Score™ of 57/100 and a GF Value™ of NT$70.97 (Possible Value Trap). The stock has 2 warning signs investors should review.

GlycoNex's Long-Term Debt for the quarter that ended in Mar. 2026 was NT$475.96 Mil.

GlycoNex's quarterly Long-Term Debt increased from Sep. 2025 (NT$471.17 Mil) to Dec. 2025 (NT$473.56 Mil) and increased from Dec. 2025 (NT$473.56 Mil) to Mar. 2026 (NT$475.96 Mil).

GlycoNex's annual Long-Term Debt stayed the same from Dec. 2023 (NT$0.00 Mil) to Dec. 2024 (NT$0.00 Mil) but then increased from Dec. 2024 (NT$0.00 Mil) to Dec. 2025 (NT$473.56 Mil).

GlycoNex  (ROCO:4168) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

GlycoNex Long-Term Debt Related Terms

GlycoNex Long-Term Debt Historical Data

* Premium members only.

The historical data trend for GlycoNex's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex Long-Term Debt Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 218.68 0.00 0.00 473.56

GlycoNex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 471.17 473.56 475.96
ROCO:4168
57GF Score
GlycoNex Inc ROCO:4168
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$475.96 Mil mean?
GlycoNex (ROCO:4168) has a Long-Term Debt of NT$475.96 Mil as of Mar. 2026.
Is GlycoNex's Long-Term Debt too high?
GlycoNex's current Long-Term Debt is NT$475.96 Mil. Overall, GlycoNex has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Long-Term Debt compare to VRTX and REGN?
GlycoNex's Long-Term Debt of NT$475.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. GlycoNex's current Long-Term Debt is NT$475.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.97, compared to a current price of NT$22.70 — trading 68% below its estimated fair value. The current Long-Term Debt is NT$475.96 Mil. GlycoNex's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Long-Term Debt is NT$475.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$22.70 is trading 68% below its estimated GF Value™ of NT$70.97. GuruFocus considers GlycoNex to be Possible Value Trap.

Key valuation signals for ROCO:4168:

  • Long-Term Debt: NT$475.96 Mil
  • GF Value™: NT$70.97 vs. price of NT$22.70 (68% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
57GF Score

Get the complete analysis for ROCO:4168

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.70
Price
NT$70.97
GF Value